16835: IPG Gets A Shot In The Ass, Feels Better.

 

MediaPost reported IPG Mediabrands won a shootout for Amgen U.S. media duties—estimated at $289 million—beating incumbents including Omnicom and WPP.

 

So apropos how pharmaceutical clients dramatically impact the health and well-being of White advertising agencies. Why, it was only months ago when IPG experienced serious adverse reactions from Pfizer shifting creative business to Publicis Groupe.

 

Of course, the people serving White advertising agencies ultimately feel most sick from such drug-induced trauma.

 

IPG Mediabrands Wins Amgen U.S. Media Review

 

By Steve McClellan

 

Thousand Oaks, CA-based biotechnology company Amgen has selected IPG Mediabrands to handle its U.S. media agency assignments after a formal review that began earlier this year.  

 

Incumbents included Omnicom and WPP. 

 

Spending on U.S. media is estimated at $289 million, according to agency research firm COMvergence.  

 

Amgen issued a brief statement: “After a four-month RFP process, we have awarded our US media business to IPG Mediabrands. We look forward to partnering with IPG Mediabrands which was selected for its best-in-class capabilities and strong talent.” Amgen has acquired several companies over the years including Horizon Therapeutics, deCODE Genetics, Micromet Inc., and Onyx Pharmaceuticals.   

 

Amgen retained MediaLink to assist with the review process.